Inflammatory Bowel Diseases (IBD)

Latest News

Diet Modifications Decrease Intestinal Inflammation in Patients With Diverticulitis

By

Virginia A. Schad, PharmD, RPh

While the etiopathogenesis of diverticulitis is not completely understood, recent evidence suggests that chronic inflammation and alterations in the gut microbiome may be key factors in the development of diverticulitis.

Molecular Evidence Suggests Similar Treatment Targets for IBD or COVID-19

By

Jessica Nye, PhD

Therapies for the treatment of inflammatory bowel disease may have a potential use in patients with COVID-19.

Multimodal Intervention Reduces Opioid Use Among Hospitalized Patients With IBD

By

Virginia A. Schad, PharmD, RPh

Multimodal interventions encouraging the use of nonopioid analgesics reduce intravenous opioid exposure in patients hospitalized with IBD.

Vedolizumab Is Safe Long-Term for Ulcerative Colitis and Crohn Disease

By

Colby Stong

Alimentary Pharmacology and Therapeutics reports on the final results from the GEMINI long-term safety study on vedolizumab, a gut-selective α4 β7 integrin antibody approved for moderately to severely active ulcerative colitis and Crohn disease.

Pro-Inflammatory Diets May Increase Risk for Crohn Disease

By

Colby Stong

An analysis of 3 large prospective cohorts examined the association between dietary patterns with high inflammatory potential and increased risks for Crohn disease and ulcerative colitis.

Crohn Disease: Steroid IV Therapy Boosts Risk for Short Bowel Syndrome

By

Brandon May

Researchers analyzed independent risk factors for short bowel syndrome in patients with Crohn disease in an effort to develop preventive strategies.

Outcomes of Creatine Kinase Levels in Tofacitinib-Treated Ulcerative Colitis Examined

By

Emily Pond

Although tofacitinib may result in elevated creatine kinase levels, effects are reversible and not associated with significant adverse events.

Fertility Rates Lower in Women With Inflammatory Bowel Disease

Fertility is lower in women with inflammatory bowel disease.

Prevalence of Adverse Pregnancy Outcomes Assessed With Biologics for IBD

By

Cassandra Pardini, PharmD

The study aimed to determine the prevalence of adverse pregnancy outcomes associated with biologic use in women with IBD.

Inflammatory Bowel Disease and the Risk of Extraintestinal Cancers

By

C. Andrew Kistler, MD, PharmD

A team of investigators conducted a systematic review and meta-analysis to assess the risk of extraintestinal cancer in patients with inflammatory bowel disease.

IBDDI More Reliably Measures IBD-Related Disability Among Different Cultures Than Generic Tools

By

Brandon May

Researchers compared the predictive properties of the IBDDI from among 5populations of individuals living with IBD, most of whom had Crohn disease as well.

Tofacitinib Therapy Did Not Alter Lipid Levels Among Patients With Colitis

By

Jessica Nye, PhD

Investigators evaluated data on lipid levels and cardiovascular events in addition to recommendations for managing lipid levels during tofacitinib treatment in patients with ulcerative colitis, according to up-to-date expert guidelines.

Histo-Endoscopic Mucosal Healing Achieved With Ustekinumab Therapy in Ulcerative Colitis

By

Virginia A. Schad, PharmD, RPh

Histo-endoscopic mucosal healing after induction therapy of ustekinumab is associated with lower disease activity at the conclusion of maintenance therapy.

Poor Diagnostic Power of Functional Bowel Disorders With Colonoscopy

By

Jessica Nye, PhD

Investigators examined the diagnostic yield of colonoscopies for patients with functional bowel disorders without alarm features.

Primary Sclerosing Cholangitis With Ulcerative Colitis Presents as a Unique Disease Phenotype

By

Jessica Nye, PhD

Researchers studied the histologic and clinical features of primary sclerosing cholangitis patients with and without IBD to predict disease severity.

High Asymptomatic COVID-19 Infection Rate Among Patients Treated With Biologics for Inflammatory Bowel Disease

By

Jessica Nye, PhD

Is treatment of inflammatory bowel disease (IBD) with biologic therapies harmful during infection with COVID-19?

Malignancy Risk Low After Long-Term Treatment With Tofacitinib for Ulcerative Colitis

By

Jessica Nye, PhD

Researchers assessed malignancy frequency in the tofacitinib ulcerative colitis clinical development program, along with frequency of malignancy events and rates.

Cannabis May Improve Quality of Life for IBD Patients

By

Heather R. Johnson

Although cannabis use does not induce clinical remission in IBD, patient-reported quality of life may improve.

Crohn Disease Recurrence Associated With Positive Resection Margins, Other Risk Factors

By

Colby Stong

Positive resection margins, granulomas, and myenteric plexitis are all predictive of postoperative Crohn disease recurrence.

Using AI for Fully Automated Endoscopic Disease Activity Assessment in Ulcerative Colitis

By

Virginia A. Schad, PharmD, RPh

An AI-powered, fully automated video analysis system may potentially provide endoscopic disease grading in ulcerative colitis that is equal to the scoring of experienced reviewers.